Elevai Labs, Inc. is a public company focused on advancing health technology through innovative artificial intelligence solutions
The company specializes in developing AI-driven platforms that enhance medical diagnostics, treatment planning, and patient care. By leveraging machine learning algorithms and data analysis, Elevai Labs aims to improve the accuracy and efficiency of healthcare delivery, ultimately transforming the way medical professionals make decisions and interact with patients. Their commitment to research and development positions them at the forefront of a rapidly evolving sector, addressing critical challenges in healthcare with cutting-edge technology.
The session on Monday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.
The US market is yet to commence its session on Monday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
NEWPORT BEACH, Calif., March 10, 2025 (GLOBE NEWSWIRE) -- Northstrive Biosciences Inc. (“Northstrive”), a subsidiary of PMGC Holdings Inc. (NASDAQELAB) (the “Company,” “PMGC,” “we,” or “our”), announced that it has scheduled a pre-Investigational New Drug (“pre-IND”) meeting with the U.S. Food and Drug Administration (“FDA”) for Wednesday, April 23, 2025. Northstrive will have a Type B pre-IND meeting with the FDA to discuss the path forward for filing an IND for EL-22 as a combination treatment with GLP-1 for muscle preservation.
Let's have a look at what is happening on the US markets one hour before the close of the markets on Thursday. Below you can find the top gainers and losers in today's session.
NEWPORT BEACH, Calif., March 06, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQELAB) (“PMGC” or the “Company”) today announced that it will effect a 1-for-7 reverse stock split (the “Split”) of its issued and outstanding common stock, par value $0.0001 per share (“Common Stock”), effective at midnight, Eastern time, on March 10, 2025.
NEWPORT BEACH, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (the “Company” or “PMGC,” “our,” or “we”) (Nasdaq: ELAB), a diversified holding company, is proud to announce its annual sponsorship of TCA Venture Group’s (“TCA”) Orange County network for 2025. As a Southern California Network Sponsor, PMGC is actively pursuing investments and M&A opportunities to strengthen its portfolio while fostering local business growth and expanding its market presence.
NEWPORT BEACH, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (the “Company,” “PMGC,” “us,” or “we”) (Nasdaq:ELAB), a diversified holding company, today announced an update on its capital structure, highlighting its financial position and ongoing commitment to executing its strategic priorities through its operating subsidiaries.
NEWPORT BEACH, Calif., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Northstrive Biosciences, a subsidiary of PMGC Holdings Inc. (NASDAQELAB) (“PMGC,” “we,” or “our”), announced the submission of a pre-IND meeting request to the FDA. Northstrive anticipates having a Type B pre-IND meeting with the FDA in the second fiscal quarter of 2025.
NEWPORT BEACH, Calif., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Northstrive Biosciences Inc. ("Northstrive"), a subsidiary of PMGC Holdings Inc. (NASDAQELAB) ("PMGC," "we," or "our"), announced an update for its innovative obesity treatment candidates, EL-22 and EL-32, both aimed at optimizing fat loss while preserving muscle mass in patients undergoing weight loss therapies, including GLP-1 receptor agonists.
NEWPORT BEACH, Calif., Jan. 31, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (the “Company” or “PMGC”) (Nasdaq: ELAB) is pleased to announce that its operating investment division, PMGC Capital LLC, has begun building its portfolio with strategic investments in the fire prevention technology and the U.S. uranium energy market. These initial investments underscore the Company's commitment to financing innovation in essential industries with significant growth opportunities.
NEWPORT BEACH, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (formerly Elevai Labs Inc.) (the “Company” or “PMGC”) (Nasdaq: ELAB), today announced that its subsidiary, Northstrive Biosciences Inc. (“Northstrive Biosciences”), has executed a research agreement (“Research Agreement”) with a leading preclinical contract research organization (“CRO”) specializing in metabolic disorders. This Research Agreement will support a preclinical study carried out by the CRO and designed to evaluate EL-32, a novel engineered probiotic, as a monotherapy and in combination with the GLP-1 receptor agonist semaglutide, focusing on its impact on glycemic control and body composition in diet-induced obese (DIO) mice. Pursuant to the research agreement, within three months of completion of this study, the CRO will provide results of this study to Northstrive Biosciences and deliver a report to Northstrive Biosciences describing the work envisaged in the Research Agreement.
Wondering how the US markets performed in the middle of the day on Monday? Discover the movers and shakers of today's session in our comprehensive analysis.
NEWPORT BEACH, Calif., Jan. 27, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (formerly Elevai Labs Inc.) (the “Company” or “PMGC”) (Nasdaq: ELAB) a diversified holding company today announced it has entered into a warrant inducement agreement with existing institutional investors for the exercise of certain outstanding Series A warrants that the Company issued on September 24, 2024. Pursuant to the warrant inducement agreement, the investors have agreed to exercise the outstanding warrants to purchase an aggregate of 969,385 shares of the Company's common stock at an amended exercise price of $2.00. The gross proceeds from the exercise of the warrants are expected to be approximately $1.9 million, prior to deducting placement agent fees and estimated offering expenses.
Curious about the most active stocks in today's session? Get a glimpse into the stocks that are generating the highest trading volume and capturing market attention.
